We are live on
!
Find out more
Barrow, Hanley, Mewhinney & Strauss Portfolio holdings
AUM
$30.5B
1-Year Est. Return
29.95%
This Fund
S&P 500
This Quarter
Est. Return
+3.22%
1 Year Est. Return
+29.95%
3 Year Est. Return
+81.25%
5 Year Est. Return
+106.98%
10 Year Est. Return
+342.87%
AUM
$65.7B
AUM Growth
+$262M
(+0.4%)
Cap. Flow
-$1.29B
Cap. Flow
% of AUM
-1.96%
Top 10 Holdings %
Top 10 Hldgs %
26.53%
Holding
362
New
36
Increased
82
Reduced
200
Closed
39
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Teva Pharmaceuticals
TEVA
|
+$713M |
| 2 |
Cardinal Health
CAH
|
+$533M |
| 3 |
ESRX
Express Scripts Holding Company
ESRX
|
+$358M |
| 4 |
Fidelity National Financial
FNF
|
+$181M |
| 5 |
Elevance Health
ELV
|
+$179M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Medtronic
MDT
|
+$518M |
| 2 |
Entergy
ETR
|
+$423M |
| 3 |
Honeywell
HON
|
+$287M |
| 4 |
CenterPoint Energy
CNP
|
+$264M |
| 5 |
Johnson & Johnson
JNJ
|
+$241M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 21.02% |
| 2 | Healthcare | 19.84% |
| 3 | Industrials | 14.73% |
| 4 | Energy | 11.33% |
| 5 | Technology | 9.71% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Philip Morris
PM
$301B
| $1.98B | 3.02% |
19,474,260
-1,439,845
| -7% | -$144M |
|
2
JPMorgan Chase
JPM
$939B
| $1.87B | 2.85% |
30,137,691
-896,353
| -3% | -$56M |
|
|
3
Medtronic
MDT
$107B
| $1.83B | 2.79% |
21,090,262
-6,404,245
| -23% | -$518M |
|
4
Verizon
VZ
$194B
| $1.8B | 2.73% |
32,152,996
-1,168,729
| -4% | -$60.6M |
|
5
Wells Fargo
WFC
$261B
| $1.79B | 2.73% |
37,842,797
-866,558
| -2% | -$42.2M |
|
6
Johnson Controls International
JCI
$87.5B
| $1.74B | 2.65% |
37,539,579
+903,548
| +2% | +$39.8M |
|
7
Pfizer
PFE
$140B
| $1.72B | 2.63% |
51,626,176
-4,999,727
| -9% | -$160M |
|
|
8
Johnson & Johnson
JNJ
$635B
| $1.6B | 2.44% |
13,210,591
-2,116,874
| -14% | -$241M |
|
9
RTX Corp
RTX
$287B
| $1.56B | 2.37% |
24,110,742
-400,047
| -2% | -$25.6M |
|
10
Merck
MRK
$324B
| $1.53B | 2.33% |
27,788,841
-154,519
| -0.6% | -$8.22M |
|
11
PNC Financial Services
PNC
$100B
| $1.51B | 2.3% |
18,537,591
-319,448
| -2% | -$27.5M |
|
12
Oracle
ORCL
$331B
| $1.48B | 2.26% |
36,227,871
+14,500
| +0% | +$579K |
|
13
Air Products & Chemicals
APD
$66.3B
| $1.47B | 2.24% |
11,183,538
-219,594
| -2% | -$29.2M |
|
14
Occidental Petroleum
OXY
$57B
| $1.44B | 2.19% |
19,041,708
-1,615,889
| -8% | -$121M |
|
15
BP
BP
$113B
| $1.42B | 2.16% |
47,464,472
+3,119,419
| +7% | +$84M |
|
16
Altria Group
MO
$122B
| $1.36B | 2.07% |
19,714,071
-261,681
| -1% | -$16.8M |
|
17
Microsoft
MSFT
$2.84T
| $1.28B | 1.95% |
25,085,291
-2,267,169
| -8% | -$118M |
|
18
Capital One
COF
$124B
| $1.26B | 1.92% |
19,814,087
+1,763,210
| +10% | +$123M |
|
19
ConocoPhillips
COP
$147B
| $1.24B | 1.89% |
28,533,558
-128,811
| -0.4% | -$5.68M |
|
20
American Express
AXP
$223B
| $1.21B | 1.85% |
19,981,729
-727,913
| -4% | -$46.1M |
|
21
Sanofi
SNY
$104B
| $1.18B | 1.79% |
28,122,279
-965,511
| -3% | -$39.6M |
|
22
Qualcomm
QCOM
$176B
| $1.16B | 1.76% |
21,598,005
+1,086,071
| +5% | +$57.2M |
|
23
Phillips 66
PSX
$82.9B
| $1.16B | 1.76% |
14,562,698
+459,964
| +3% | +$37.6M |
|
|
24
Honeywell
HON
$77.1B
| $1.15B | 1.75% |
11,007,093
-2,790,241
| -20% | -$287M |
|
|
25
Teva Pharmaceuticals
TEVA
$35.9B
| $1.14B | 1.74% |
22,700,812
+13,385,352
| +144% | +$713M |
|
Similar funds
Barrow, Hanley, Mewhinney & Strauss's Q2 2016 Portfolio in Review
As of Q2 2016, Barrow, Hanley, Mewhinney & Strauss held 362 positions worth $65.7B, up 0.4% from $65.4B the previous quarter. Its ten largest holdings account for 27% of the portfolio.
Barrow, Hanley, Mewhinney & Strauss's Q2 2016 filing shows 36 new, 82 increased, 200 reduced and 39 closed positions. Its largest new stake was Fidelity National Financial: 7,688,148 shares worth $200M. The largest sale was Medtronic, an estimated $518M.
By sector, the portfolio is most concentrated in Financials at 21% of assets, down from 21% a quarter earlier, followed by Healthcare and Industrials.
- Barrow, Hanley, Mewhinney & Strauss's largest Q2 2016 buy was Fidelity National Financial: 7,688,148 shares worth $200M.
- Barrow, Hanley, Mewhinney & Strauss added most to Teva Pharmaceuticals in Q2 2016, an estimated $713M increase.
- Barrow, Hanley, Mewhinney & Strauss's biggest Q2 2016 reduction was Medtronic, cutting an estimated $518M.
- Barrow, Hanley, Mewhinney & Strauss fully exited People's United Financial Inc in Q2 2016, selling an estimated $180M.
- Barrow, Hanley, Mewhinney & Strauss's ten largest holdings make up 27% of its $65.7B portfolio in Q2 2016.
- Barrow, Hanley, Mewhinney & Strauss opened 36 new positions and closed 39 in Q2 2016.
- Barrow, Hanley, Mewhinney & Strauss's portfolio value rose 0.4% quarter-over-quarter to $65.7B.
Based on Barrow, Hanley, Mewhinney & Strauss's 13F filing for Q2 2016, filed 8 Aug 2016.